Details

Autor(en) / Beteiligte

• Gallina, F.T.
• Marinelli, D.
• Melis, E.
• Forcella, D.
• Taje, R.
• Buglioni, S.
• Visca, P.
• Torchia, A.
• Cecere, F.L.
• Botticelli, A.
• Santini, D.
• Ciliberto, G.
• Cappuzzo, F.
• Facciolo, F.

Titel

KRAS G12C mutation and risk of disease recurrence in stage I surgically resected lung adenocarcinoma

Ist Teil von

• Lung cancer (Amsterdam, Netherlands), 2023-07, Vol.181, p.107254-107254, Article 107254

Ort / Verlag

Ireland: Elsevier B.V

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• •It is unclear whether the KRAS G12C has a prognostic role in early stage LUAD.•In the stage I IRE cohort we found an association between KRAS G12C and worse DFS.•In the TCGA cohort, an association between the KRAS G12C and DFS was not found.•In the MSK LUAD604 cohort KRAS G12C had worse RFS when compared to KRAS nonG12C.•In the pooled cohort KRAS G12C had worse DFS than KRAS nonG12C and KRAS wild type. KRAS G12C mutations are found in about 12–13% of LUAD samples and it is unclear whether they are associated with worse survival outcomes in resected, stage I LUAD. We assessed whether KRAS-G12C mutated tumours had worse DFS when compared to KRAS-nonG12C mutated tumours and to KRAS wild-type tumours in a cohort of resected, stage I LUAD (IRE cohort). We then leveraged on publicly available datasets (TCGA-LUAD, MSK-LUAD604) to further test the hypothesis in external cohorts. In the stage I IRE cohort we found a significant association between the KRAS-G12C mutation and worse DFS in multivariable analysis (HR: 2.47). In the TCGA-LUAD stage I cohort we did not find statistically significant associations between the KRAS-G12C mutation and DFS. In the MSK-LUAD604 stage I cohort we found that KRAS-G12C mutated tumours had worse RFS when compared to KRAS-nonG12C mutated tumours in univariable analysis (HR 3.5). In the pooled stage I cohort we found that KRAS-G12C mutated tumours had worse DFS when compared to KRAS-nonG12C mutated tumours (HR 2.6), to KRAS wild-type tumours (HR 1.6) and to any other tumours (HR 1.8); in multivariable analysis, the KRAS-G12C mutation was associated with worse DFS (HR 1.61). Our results suggest that patients with resected, stage I LUAD with a KRAS-G12C mutation may have inferior survival outcomes..